RESUMEN
O objetivo do trabalho foi verificar a presença de efeitos colaterais avaliados pelo método de avaliação clínica e laboratorial em cães com dermatopatias tratados com prednisona em dose anti-inflamatória. Para isso, foram utilizados 11 cães que apresentassem alguma dermatopatia alérgica. Todos esses foram submetidos à terapia com prednisona durante 20 dias, nas doses de 0,25 mg/kg/BID/5 dias, 0,25 mg/kg/Sid/5 dias e 0,25 mg/kg/EDA/10 dias. Exames laboratoriais (hemograma, bioquímicos da função renal, função e lesão hepática, glicemia, colesterol, triglicérides, urinálise, UPC e pressão arterial sistêmica) foram realizados em dois momentos (antes e após o tratamento). Após análise dos resultados não foram observadas alterações estatísticas relacionadas à utilização do corticoide entre os dois momentos estudados. Por tanto, conclui-se que a ausência de alterações pode sugerir que a dose e o tempo de tratamento foram seguros, porém estudos com a utilização de prednisona em doses mais altas e com períodos maiores devem ser realizados afim de demonstrar a relação da corticoidoterapia com efeitos colaterais.
The skin affections are of great importance in the small animal clinic, corresponding to a large percentage of the cases attended in the clinical routine. The most frequent dermatopathies are allergic dermatitis to ectoparasite bite,cutaneous neoplasm, bacterial pyoderma, seborrhea, allergic dermatitis, parasitic dermatitis and immune mediated dermatoses. However, allergic dermatitis is the most commonly treated with corticosteroids. The objective of the study was to verify the presence of side effects evaluated by the clinical and laboratory evaluation method in dogs with dermatopathies treated with prednisone in an anti-inflammatory dose. For this, 11 dogs were used that had some allergic dermatopathy. All of these patients underwent prednisone therapy for 20 days at doses of 0,25 mg/kg/BID/5 dias, 0,25mg/kg/Sid/5 dias e 0,25 mg/kg/EDA/10 dias. Laboratory tests (hemogram, biochemicals of renal function, liverfunction and lesion, glucose, cholesterol, triglycerides, urinalysis, UPC and systemic arterial pressure) were done at two moments (before and after treatment). After analyzing the results, no statistical changes related to the use of corticosteroids were observed between the two moments studied. Therefore, it is concluded that the absence of alterations may suggest that the dose and the time of treatment were safe, but studies with the use of prednisone at higher doses, with longer periods and with a greater number of animals, should be performed in order to demonstrate the relationship of corticoid therapy with side effects.
Asunto(s)
Animales , Perros , Dermatitis Alérgica por Contacto/veterinaria , Enfermedades de los Perros/tratamiento farmacológico , Prednisona/administración & dosificación , Prednisona/efectos adversos , Prednisona/sangre , Prednisona/orina , Prednisona/uso terapéutico , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/veterinariaRESUMEN
O objetivo do trabalho foi verificar a presença de efeitos colaterais avaliados pelo método de avaliação clínica e laboratorial em cães com dermatopatias tratados com prednisona em dose anti-inflamatória. Para isso, foram utilizados 11 cães que apresentassem alguma dermatopatia alérgica. Todos esses foram submetidos à terapia com prednisona durante 20 dias, nas doses de 0,25 mg/kg/BID/5 dias, 0,25 mg/kg/Sid/5 dias e 0,25 mg/kg/EDA/10 dias. Exames laboratoriais (hemograma, bioquímicos da função renal, função e lesão hepática, glicemia, colesterol, triglicérides, urinálise, UPC e pressão arterial sistêmica) foram realizados em dois momentos (antes e após o tratamento). Após análise dos resultados não foram observadas alterações estatísticas relacionadas à utilização do corticoide entre os dois momentos estudados. Por tanto, conclui-se que a ausência de alterações pode sugerir que a dose e o tempo de tratamento foram seguros, porém estudos com a utilização de prednisona em doses mais altas e com períodos maiores devem ser realizados afim de demonstrar a relação da corticoidoterapia com efeitos colaterais.(AU)
The skin affections are of great importance in the small animal clinic, corresponding to a large percentage of the cases attended in the clinical routine. The most frequent dermatopathies are allergic dermatitis to ectoparasite bite,cutaneous neoplasm, bacterial pyoderma, seborrhea, allergic dermatitis, parasitic dermatitis and immune mediated dermatoses. However, allergic dermatitis is the most commonly treated with corticosteroids. The objective of the study was to verify the presence of side effects evaluated by the clinical and laboratory evaluation method in dogs with dermatopathies treated with prednisone in an anti-inflammatory dose. For this, 11 dogs were used that had some allergic dermatopathy. All of these patients underwent prednisone therapy for 20 days at doses of 0,25 mg/kg/BID/5 dias, 0,25mg/kg/Sid/5 dias e 0,25 mg/kg/EDA/10 dias. Laboratory tests (hemogram, biochemicals of renal function, liverfunction and lesion, glucose, cholesterol, triglycerides, urinalysis, UPC and systemic arterial pressure) were done at two moments (before and after treatment). After analyzing the results, no statistical changes related to the use of corticosteroids were observed between the two moments studied. Therefore, it is concluded that the absence of alterations may suggest that the dose and the time of treatment were safe, but studies with the use of prednisone at higher doses, with longer periods and with a greater number of animals, should be performed in order to demonstrate the relationship of corticoid therapy with side effects.(AU)
Asunto(s)
Animales , Perros , Prednisona/administración & dosificación , Prednisona/efectos adversos , Prednisona/sangre , Prednisona/uso terapéutico , Prednisona/orina , Dermatitis Alérgica por Contacto/veterinaria , Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/veterinariaRESUMEN
A high-performance liquid chromatographic technique for the simultaneous determination of prednisolone and prednisone in human plasma, whole blood, urine, and bound-to-plasma proteins, using betamethasone as internal standard, is presented. Liquid-liquid extraction is used for whole blood samples, and solid phase extraction is used for plasma, urine, and proteins bound to plasma. The accuracy, precision, specificity, linearity, and repeatability meet the requirements of current recommendations in bioanalytical method validation. The method is suitable for high altitude pharmacokinetic studies, in which the quantitation of drugs in those fluids is required. The results from healthy volunteers are presented.